# Phase 1 Dose-escalation PK/PD Trial in Advanced Cancer Patients

> **NCT00610194** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 69 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** RDEA119

## Key facts

- **NCT ID:** NCT00610194
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11-28
- **Primary completion:** 2010-11-24
- **Final completion:** 2012-08-01
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2023-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00610194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00610194, "Phase 1 Dose-escalation PK/PD Trial in Advanced Cancer Patients". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00610194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*